OncoPharm

The Landmarks of OncoPharm series returns to discuss 2 landmark studies (and 1 editorial) in head & neck cancer.

Editorial: https://ascopubs.org/doi/pdf/10.1200/JCO.22.00274

EUORTC Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032641

Intergroup Study: https://www.nejm.org/doi/full/10.1056/NEJMoa032646

The highlights, and only the highlights, of melanoma.

Treatment-free remission (TFR) rates in CML of close to 80% have recently been described (https://doi.org/10.1002/ajh.26550).

The AGILE study. If you can't say anything nice.

Checking back in on CHECKMATE 816 (neoadjuvant Nico-Chemo in NSCLC) and Keynote-177 (pembrolizumab in MSI-H/dMMR colorectal cancer).

Ribociclib-Tamoxifen: A Cautionary Tale by John Bossaer

Catching on recent FDA approvals on relatlimab/nivolumab (it's relatLimab not relatimab) as well as Lu-PSMA-177 based on the VISION trial.

Open up your Yelp app and check out Leukemia Pharmacist & Boston denizen Jessie Signorelli's recommendations for eating, drinking, & sight seeing in Boston.

Also, great educational programming awaits!

Trastuzumab deruxtecan vs. trastuzumab trastuzumab

We look at two recent studies that illustrate a framework for how we identify risk factors and possible predictors of chemotherapy toxicity.

Paclitaxel and skeletal muscle mass: https://doi.org/10.1111/bcp.15244

Sex differences of toxicity risk: https://doi.org/10.1200/jco.21.02377

Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.

The Landmarks of OncoPharm series returns to discuss the origins of "7 + 3"

7 + 3 > 5 + 2: https://doi.org/10.1182/blood.V58.6.1203.1203